Abstract
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Highlights
Important therapeutic target, since glomerular hyperfiltration is a potential driver of renal disease progression in type 2 diabetes [1]
The efficacy and safety of dapagliflozin in 252 patients with type 2 diabetes and moderate renal impairment has previously been assessed in a paper by Kohan and colleagues [5]
We examined whether changes in urinary albumin/creatinine ratio (UACR) occur independently of sex and changes in HbA1c, BP, uric acid and estimated GFR
Summary
Important therapeutic target, since glomerular hyperfiltration is a potential driver of renal disease progression in type 2 diabetes [1]. Changes in albuminuria predict morbidity and mortality, as well as cardiovascular and renal outcomes in patients with type 2 diabetes [3], and a short-term beneficial effect of dapagliflozin on albumin excretion has been reported [4]. We conducted a post hoc analysis of data from this study to examine the long-term effects of dapagliflozin on urinary albumin/creatinine ratio (UACR) in patients with UACR ≥3.4 mg/mmol (≥30 mg/g) at baseline.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
